100,012 Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 100,012 shares of the company's stock, valued at approximately $339,000. BNP Paribas Financial Markets owned 0.07% of Xeris Biopharma as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in Xeris Biopharma by 166.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock valued at $3,537,000 after acquiring an additional 651,481 shares during the last quarter. Renaissance Technologies LLC boosted its position in Xeris Biopharma by 31.3% during the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock valued at $7,115,000 after acquiring an additional 500,120 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in Xeris Biopharma during the fourth quarter valued at $1,610,000. AIGH Capital Management LLC boosted its position in Xeris Biopharma by 17.8% during the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company's stock valued at $8,729,000 after acquiring an additional 389,192 shares during the last quarter. Finally, EAM Investors LLC bought a new stake in Xeris Biopharma during the fourth quarter valued at $754,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on XERS. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Wall Street Zen cut shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners increased their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research report on Friday, March 7th. Finally, Craig Hallum increased their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Xeris Biopharma has an average rating of "Moderate Buy" and an average target price of $6.25.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.47% of the stock is currently owned by company insiders.

Xeris Biopharma Trading Down 2.2%

Shares of XERS stock traded down $0.11 during trading hours on Friday, hitting $4.93. 2,399,990 shares of the company were exchanged, compared to its average volume of 1,953,480. The firm has a fifty day simple moving average of $4.65 and a 200 day simple moving average of $4.02. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.03 and a 52-week high of $6.07. The stock has a market capitalization of $770.98 million, a price-to-earnings ratio of -10.96 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.